25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aquestive Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Aquestive together

I guess you are interested in Aquestive Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aquestive Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aquestive Therapeutics Inc

I send you an email if I find something interesting about Aquestive Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aquestive (30 sec.)










1.2. What can you expect buying and holding a share of Aquestive? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
9.4%

What is your share worth?

Current worth
$-0.50
Expected worth in 1 year
$0.13
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.63
Return On Investment
14.6%

For what price can you sell your share?

Current Price per Share
$4.31
Expected price per share
$3.02 - $5.8
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aquestive (5 min.)




Live pricePrice per Share (EOD)
$4.31
Intrinsic Value Per Share
$-3.02 - $-3.55
Total Value Per Share
$-3.52 - $-4.05

2.2. Growth of Aquestive (5 min.)




Is Aquestive growing?

Current yearPrevious yearGrowGrow %
How rich?-$45.4m-$109.3m$53.4m95.5%

How much money is Aquestive making?

Current yearPrevious yearGrowGrow %
Making money-$8.7m-$1.6m-$7.1m-81.0%
Net Profit Margin-66.6%-14.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Aquestive (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aquestive?

Welcome investor! Aquestive's management wants to use your money to grow the business. In return you get a share of Aquestive.

First you should know what it really means to hold a share of Aquestive. And how you can make/lose money.

Speculation

The Price per Share of Aquestive is $4.31. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aquestive.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aquestive, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.50. Based on the TTM, the Book Value Change Per Share is $0.16 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aquestive.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.13-2.9%-0.10-2.2%-0.03-0.8%-0.13-2.9%-0.13-3.0%
Usd Book Value Change Per Share-0.11-2.5%0.163.7%0.010.3%-0.01-0.1%-0.02-0.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.11-2.5%0.163.7%0.010.3%-0.01-0.1%-0.02-0.5%
Usd Price Per Share4.98-3.47-1.31-3.20-3.19-
Price to Earnings Ratio-9.86--11.18--5.52--8.66--7.17-
Price-to-Total Gains Ratio-45.68-49.13-24.77--50.75--44.86-
Price to Book Ratio-10.00--7.28--1.10--10.18--6.45-
Price-to-Total Gains Ratio-45.68-49.13-24.77--50.75--44.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.31
Number of shares232
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.16-0.01
Usd Total Gains Per Share0.16-0.01
Gains per Quarter (232 shares)36.58-1.39
Gains per Year (232 shares)146.32-5.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101461360-6-16
202932820-11-22
304394280-17-28
405855740-22-34
507327200-28-40
608788660-33-46
70102410120-39-52
80117111580-45-58
90131713040-50-64
100146314500-56-70

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%3.029.00.09.4%3.031.00.08.8%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%6.014.00.030.0%8.021.03.025.0%9.022.03.026.5%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.029.09.4%3.00.031.08.8%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%6.014.00.030.0%8.021.03.025.0%9.022.03.026.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aquestive Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1090.158-169%0.013-913%-0.006-94%-0.022-80%
Book Value Per Share---0.498-0.613+23%-1.199+141%-0.735+47%-0.524+5%
Current Ratio--6.3735.594+14%1.220+422%2.696+136%2.237+185%
Debt To Asset Ratio--1.4131.712-17%2.879-51%2.096-33%1.835-23%
Debt To Equity Ratio----0%-0%-0%0.327-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Enterprise Value--376582436.000228093463.000+65%-23279830.445+106%191316907.379+97%285284302.703+32%
Eps---0.126-0.096-24%-0.033-74%-0.125-1%-0.127+1%
Ev To Ebitda Ratio---13.16435.501-137%-0.077-99%7.535-275%2.756-578%
Ev To Sales Ratio--6.9524.135+68%-0.548+108%4.018+73%5.699+22%
Free Cash Flow Per Share---0.131-0.094-28%0.016-897%-0.077-42%-0.072-45%
Free Cash Flow To Equity Per Share---0.1310.145-190%0.017-864%0.031-520%0.022-688%
Gross Profit Margin--1.0001.0000%1.0000%1.0020%1.0010%
Intrinsic Value_10Y_max---3.550--------
Intrinsic Value_10Y_min---3.023--------
Intrinsic Value_1Y_max---0.232--------
Intrinsic Value_1Y_min---0.228--------
Intrinsic Value_3Y_max---0.792--------
Intrinsic Value_3Y_min---0.754--------
Intrinsic Value_5Y_max---1.465--------
Intrinsic Value_5Y_min---1.352--------
Market Cap392978042.000-16%454067436.000315932463.000+44%119035419.555+281%291756107.379+56%290906611.487+56%
Net Profit Margin---0.850-0.666-22%-0.140-84%-1.047+23%-0.975+15%
Operating Margin---0.540-0.404-25%-0.160-70%-0.693+28%-0.676+25%
Operating Ratio--1.6121.412+14%1.479+9%1.748-8%1.715-6%
Pb Ratio-8.652+13%-9.997-7.277-27%-1.103-89%-10.181+2%-6.454-35%
Pe Ratio-8.536+13%-9.863-11.175+13%-5.519-44%-8.662-12%-7.169-27%
Price Per Share4.310-16%4.9803.465+44%1.306+281%3.200+56%3.191+56%
Price To Free Cash Flow Ratio-8.214+13%-9.491-9.130-4%-3.219-66%-7.808-18%-7.883-17%
Price To Total Gains Ratio-39.531+13%-45.67649.130-193%24.774-284%-50.751+11%-44.865-2%
Quick Ratio--5.7805.045+15%0.973+494%2.357+145%1.918+201%
Return On Assets---0.105-0.092-12%-0.037-65%-0.185+76%-0.199+90%
Return On Equity----0%-0%-0%-0.0630%
Total Gains Per Share---0.1090.158-169%0.013-911%-0.006-94%-0.022-80%
Usd Book Value---45420000.000-55921750.000+23%-109341750.000+141%-66988700.000+47%-47812156.250+5%
Usd Book Value Change Per Share---0.1090.158-169%0.013-913%-0.006-94%-0.022-80%
Usd Book Value Per Share---0.498-0.613+23%-1.199+141%-0.735+47%-0.524+5%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.126-0.096-24%-0.033-74%-0.125-1%-0.127+1%
Usd Free Cash Flow---11960000.000-8593000.000-28%1500750.000-897%-6981550.000-42%-6564156.250-45%
Usd Free Cash Flow Per Share---0.131-0.094-28%0.016-897%-0.077-42%-0.072-45%
Usd Free Cash Flow To Equity Per Share---0.1310.145-190%0.017-864%0.031-520%0.022-688%
Usd Market Cap392978042.000-16%454067436.000315932463.000+44%119035419.555+281%291756107.379+56%290906611.487+56%
Usd Price Per Share4.310-16%4.9803.465+44%1.306+281%3.200+56%3.191+56%
Usd Profit---11509000.000-8798250.000-24%-1667500.000-86%-11679200.000+1%-11545531.250+0%
Usd Revenue--13542000.00014725000.000-8%12014750.000+13%12852850.000+5%14980656.250-10%
Usd Total Gains Per Share---0.1090.158-169%0.013-911%-0.006-94%-0.022-80%
 EOD+2 -6MRQTTM+13 -21YOY+15 -215Y+20 -1710Y+22 -16

3.3 Fundamental Score

Let's check the fundamental score of Aquestive Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.536
Price to Book Ratio (EOD)Between0-1-8.652
Net Profit Margin (MRQ)Greater than0-0.850
Operating Margin (MRQ)Greater than0-0.540
Quick Ratio (MRQ)Greater than15.780
Current Ratio (MRQ)Greater than16.373
Debt to Asset Ratio (MRQ)Less than11.413
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.105
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Aquestive Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.932
Ma 20Greater thanMa 504.811
Ma 50Greater thanMa 1004.956
Ma 100Greater thanMa 2004.520
OpenGreater thanClose4.400
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Fundamental data was last updated by Penke on 2024-12-05 12:43:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aquestive earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -85.0% means that $-0.85 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aquestive Therapeutics Inc:

  • The MRQ is -85.0%. The company is making a huge loss. -2
  • The TTM is -66.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-85.0%TTM-66.6%-18.4%
TTM-66.6%YOY-14.0%-52.6%
TTM-66.6%5Y-104.7%+38.1%
5Y-104.7%10Y-97.5%-7.2%
4.3.1.2. Return on Assets

Shows how efficient Aquestive is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • -10.5% Return on Assets means that Aquestive generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aquestive Therapeutics Inc:

  • The MRQ is -10.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-9.2%-1.3%
TTM-9.2%YOY-3.7%-5.5%
TTM-9.2%5Y-18.5%+9.3%
5Y-18.5%10Y-19.9%+1.4%
4.3.1.3. Return on Equity

Shows how efficient Aquestive is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Aquestive generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aquestive Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-6.3%+6.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aquestive Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aquestive is operating .

  • Measures how much profit Aquestive makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -54.0% means the company generated $-0.54  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aquestive Therapeutics Inc:

  • The MRQ is -54.0%. The company is operating very inefficient. -2
  • The TTM is -40.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-54.0%TTM-40.4%-13.6%
TTM-40.4%YOY-16.0%-24.4%
TTM-40.4%5Y-69.3%+28.9%
5Y-69.3%10Y-67.6%-1.7%
4.3.2.2. Operating Ratio

Measures how efficient Aquestive is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.61 means that the operating costs are $1.61 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 1.612. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.412. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.612TTM1.412+0.200
TTM1.412YOY1.479-0.067
TTM1.4125Y1.748-0.336
5Y1.74810Y1.715+0.033
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aquestive Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aquestive is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 6.37 means the company has $6.37 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 6.373. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.594. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.373TTM5.594+0.780
TTM5.594YOY1.220+4.373
TTM5.5945Y2.696+2.898
5Y2.69610Y2.237+0.458
4.4.3.2. Quick Ratio

Measures if Aquestive is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 5.78 means the company can pay off $5.78 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 5.780. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.045. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.780TTM5.045+0.735
TTM5.045YOY0.973+4.072
TTM5.0455Y2.357+2.688
5Y2.35710Y1.918+0.439
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aquestive Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aquestive assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aquestive to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.41 means that Aquestive assets are financed with 141.3% credit (debt) and the remaining percentage (100% - 141.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 1.413. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.712. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.413TTM1.712-0.299
TTM1.712YOY2.879-1.166
TTM1.7125Y2.096-0.384
5Y2.09610Y1.835+0.262
4.5.4.2. Debt to Equity Ratio

Measures if Aquestive is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y0.327-0.327
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aquestive generates.

  • Above 15 is considered overpriced but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -9.86 means the investor is paying $-9.86 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aquestive Therapeutics Inc:

  • The EOD is -8.536. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.863. Based on the earnings, the company is expensive. -2
  • The TTM is -11.175. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.536MRQ-9.863+1.327
MRQ-9.863TTM-11.175+1.312
TTM-11.175YOY-5.519-5.656
TTM-11.1755Y-8.662-2.513
5Y-8.66210Y-7.169-1.494
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aquestive Therapeutics Inc:

  • The EOD is -8.214. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.491. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.130. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.214MRQ-9.491+1.277
MRQ-9.491TTM-9.130-0.361
TTM-9.130YOY-3.219-5.911
TTM-9.1305Y-7.808-1.322
5Y-7.80810Y-7.883+0.075
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aquestive is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -10.00 means the investor is paying $-10.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aquestive Therapeutics Inc:

  • The EOD is -8.652. Based on the equity, the company is expensive. -2
  • The MRQ is -9.997. Based on the equity, the company is expensive. -2
  • The TTM is -7.277. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.652MRQ-9.997+1.345
MRQ-9.997TTM-7.277-2.720
TTM-7.277YOY-1.103-6.174
TTM-7.2775Y-10.181+2.904
5Y-10.18110Y-6.454-3.728
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aquestive Therapeutics Inc.

4.8.1. Institutions holding Aquestive Therapeutics Inc

Institutions are holding 55.375% of the shares of Aquestive Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Bratton Capital Management, L.P.10.7602100981095800
2024-09-30VR Adviser, LLC6.09311.4491555555500
2024-06-30BlackRock Inc5.98250.000354547434109867305.5945
2024-09-30Vanguard Group Inc4.67630.00044263796361240.8545
2024-09-30Franklin Resources Inc3.03420.00362766542-87700-3.0726
2024-09-30MPM Oncology Impact Management LP1.97061.3424179675017967500
2024-09-30Geode Capital Management, LLC1.82890.00071667515905435.7416
2024-09-30State Street Corp1.64160.0003149673951268252.0988
2024-09-30Blue Owl Capital Holdings LP1.34351.17671225000850007.4561
2024-09-30Janney Montgomery Scott LLC1.01260.0128923285428004.861
2024-09-30Citadel Advisors Llc0.95620.0008871833704020419.5265
2024-09-30Woodline Partners LP0.89520.034281625221529335.8249
2024-09-30Amvescap Plc.0.86270.0008786579697538783.3897
2024-09-30Essex Investment Management Company, LLC0.77550.613870707818940.2686
2024-09-30Morgan Stanley - Brokerage Accounts0.73650.0002671489-440483-39.6128
2024-09-30Dafna Capital Management LLC0.64660.69365895615956111.2379
2024-09-30Northern Trust Corp0.63790.0005581613387589199.7634
2024-09-30Bracebridge Capital, LLC0.470.348342857100
2024-09-30Qube Research & Technologies0.30980.0021282431-435669-60.6697
2024-09-30Latash Investments, LLC0.26671.114824313400
Total 44.9006106.795440939424+7775809+19.0%

4.9.2. Funds holding Aquestive Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv2.63680.0008240417000
2024-11-27iShares Russell 2000 ETF2.26690.01322066917-4312-0.2082
2024-10-31Franklin Biotechnology Discv A(acc)USD1.55420.50791417100-355500-20.0553
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.22530.00571117165-3976-0.3546
2024-09-30Franklin Biotechnology Discovery A1.090.535299380000
2024-11-27Invesco Dorsey Wright SmallCap Momt ETF0.83470.352776109000
2024-09-30Fidelity Small Cap Index0.83070.0137757393-3132-0.4118
2024-11-27iShares Russell 2000 Value ETF0.57860.01955275526820.1294
2024-08-31MEDICAL BioHealth EUR Acc0.53220.26114852884852880
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.48470.0054441984-15300-3.3458
2024-09-30Fidelity Extended Market Index0.44840.0049408864-31079-7.0643
2024-10-31Vanguard Russell 2000 ETF0.3710.0151338302-2108-0.6193
2024-09-30Arctic Aurora LifeScience I USD0.35650.68083250749007438.3294
2024-10-31State St Russell Sm Cap® Indx SL Cl I0.3150.016328720000
2024-09-30Bridgeway Ultra-Small Company Market0.20550.53318735600
2024-11-27iShares Russell 2000 Growth ETF0.20430.007218627100
2024-09-30NT R2000 Index Fund - NL0.19570.01351784311784310
2024-10-31Schwab Small Cap Index0.19270.015217567300
2024-11-27iShares Micro-Cap ETF0.18620.087916978800
2024-09-30BlackRock Extended Equity Market K0.15960.0049145533-29403-16.8079
Total 14.6693.09413374951+309665+2.3%

5.3. Insider Transactions

Insiders are holding 5.009% of the shares of Aquestive Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-26Cassie JungSELL444.87
2024-03-15Alexander Mark SchobelSELL500006
2024-03-08Alexander Mark SchobelSELL250005.19
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Net Debt  20,12054,83074,950-55,01519,9357,07927,014-68,038-41,024



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets109,958
Total Liabilities155,378
Total Stockholder Equity-45,420
 As reported
Total Liabilities 155,378
Total Stockholder Equity+ -45,420
Total Assets = 109,958

Assets

Total Assets109,958
Total Current Assets96,570
Long-term Assets13,388
Total Current Assets
Cash And Cash Equivalents 77,893
Net Receivables 9,684
Inventory 7,021
Other Current Assets 1,972
Total Current Assets  (as reported)96,570
Total Current Assets  (calculated)96,570
+/-0
Long-term Assets
Property Plant Equipment 9,158
Long-term Assets Other 4,230
Long-term Assets  (as reported)13,388
Long-term Assets  (calculated)13,388
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,152
Long-term Liabilities140,226
Total Stockholder Equity-45,420
Total Current Liabilities
Short-term Debt 507
Short Long Term Debt 25
Accounts payable 7,572
Other Current Liabilities 5,552
Total Current Liabilities  (as reported)15,152
Total Current Liabilities  (calculated)13,656
+/- 1,496
Long-term Liabilities
Long term Debt 31,253
Capital Lease Obligations 5,591
Long-term Liabilities Other 20,868
Long-term Liabilities  (as reported)140,226
Long-term Liabilities  (calculated)57,712
+/- 82,514
Total Stockholder Equity
Common Stock91
Retained Earnings -346,159
Other Stockholders Equity 300,648
Total Stockholder Equity (as reported)-45,420
Total Stockholder Equity (calculated)-45,420
+/-0
Other
Capital Stock91
Cash and Short Term Investments 77,893
Common Stock Shares Outstanding 91,082
Current Deferred Revenue1,048
Liabilities and Stockholders Equity 109,958
Net Debt -41,024
Net Invested Capital -14,142
Net Working Capital 81,418
Property Plant and Equipment Gross 52,516
Short Long Term Debt Total 36,869



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312007-06-302007-03-31
> Total Assets 
23,801
22,713
39,389
0
0
0
43,116
46,082
39,841
90,010
86,851
67,979
50,408
48,818
78,479
64,487
63,546
50,423
62,884
61,923
66,875
65,293
61,993
56,529
56,310
51,845
55,675
61,285
56,994
59,448
57,418
129,523
117,605
109,958
109,958117,605129,52357,41859,44856,99461,28555,67551,84556,31056,52961,99365,29366,87561,92362,88450,42363,54664,48778,47948,81850,40867,97986,85190,01039,84146,08243,11600039,38922,71323,801
   > Total Current Assets 
12,514
10,278
23,332
0
0
0
28,163
30,421
26,649
77,359
74,201
55,958
39,064
38,060
68,314
51,088
43,909
31,684
44,625
44,443
50,998
50,210
47,259
42,585
43,505
38,087
39,888
43,706
39,788
42,457
40,966
113,379
104,011
96,570
96,570104,011113,37940,96642,45739,78843,70639,88838,08743,50542,58547,25950,21050,99844,44344,62531,68443,90951,08868,31438,06039,06455,95874,20177,35926,64930,42128,16300023,33210,27812,514
       Cash And Cash Equivalents 
11,306
7,781
9,209
0
0
0
17,379
16,488
10,638
63,982
60,599
39,934
22,165
20,914
49,326
35,521
25,422
17,064
31,807
27,498
34,234
31,164
28,024
14,736
17,695
18,649
27,273
26,882
22,436
24,917
23,872
95,200
89,870
77,893
77,89389,87095,20023,87224,91722,43626,88227,27318,64917,69514,73628,02431,16434,23427,49831,80717,06425,42235,52149,32620,91422,16539,93460,59963,98210,63816,48817,3790009,2097,78111,306
       Net Receivables 
207
1,428
10,817
0
0
0
6,179
9,441
6,629
7,450
6,481
7,489
10,150
10,316
13,130
9,536
12,891
7,990
6,955
10,209
12,127
13,643
12,120
19,896
19,165
10,737
4,704
7,551
10,101
8,550
8,471
8,324
5,998
9,684
9,6845,9988,3248,4718,55010,1017,5514,70410,73719,16519,89612,12013,64312,12710,2096,9557,99012,8919,53613,13010,31610,1507,4896,4817,4506,6299,4416,17900010,8171,428207
       Inventory 
865
800
2,886
0
0
0
4,014
3,850
4,348
4,483
5,441
5,137
4,647
4,124
2,859
3,087
3,173
3,242
2,461
2,799
2,839
2,863
4,038
4,629
5,008
6,725
5,780
6,981
5,950
7,079
6,769
7,734
6,966
7,021
7,0216,9667,7346,7697,0795,9506,9815,7806,7255,0084,6294,0382,8632,8392,7992,4613,2423,1733,0872,8594,1244,6475,1375,4414,4834,3483,8504,0140002,886800865
   > Long-term Assets 
0
0
0
0
0
0
14,953
15,661
13,192
12,651
12,650
12,021
11,344
10,758
10,165
13,399
19,637
18,739
18,259
17,480
15,877
15,083
14,734
13,944
12,805
13,758
15,787
17,579
17,206
16,991
16,452
16,144
13,594
13,388
13,38813,59416,14416,45216,99117,20617,57915,78713,75812,80513,94414,73415,08315,87717,48018,25918,73919,63713,39910,16510,75811,34412,02112,65012,65113,19215,66114,953000000
       Property Plant Equipment 
9,579
9,796
15,122
0
0
0
13,460
12,764
12,766
12,211
12,207
11,594
10,933
10,351
9,726
12,971
12,221
11,337
10,321
9,556
8,893
8,114
7,780
7,020
6,883
6,378
7,901
9,698
10,380
10,220
9,736
9,488
9,356
9,158
9,1589,3569,4889,73610,22010,3809,6987,9016,3786,8837,0207,7808,1148,8939,55610,32111,33712,22112,9719,72610,35110,93311,59412,20712,21112,76612,76413,46000015,1229,7969,579
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
286
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000028600000000000000
       Long Term Investments 
0
0
0
0
0
0
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000066000000
       Intangible Assets 
1,605
1,546
305
0
0
0
254
241
229
216
204
191
178
165
153
140
127
115
102
89
76
64
51
38
25
1,487
1,435
1,396
1,357
1,317
1,278
1,239
0
0
001,2391,2781,3171,3571,3961,4351,4872538516476891021151271401531651781912042162292412540003051,5461,605
       Long-term Assets Other 
0
0
0
0
0
0
1,239
2,656
197
224
239
236
233
242
286
288
7,289
7,287
7,836
7,835
6,908
6,905
6,903
6,886
5,897
5,893
6,451
6,485
5,469
5,454
1,438
1,417
1,238
4,230
4,2301,2381,4171,4385,4545,4696,4856,4515,8935,8976,8866,9036,9056,9087,8357,8367,2877,2892882862422332362392241972,6561,239000000
> Total Liabilities 
2,524
4,867
56,965
0
0
0
69,611
68,902
78,789
66,566
76,771
74,035
75,065
83,277
84,601
85,316
84,934
86,942
111,381
113,721
120,644
125,638
144,127
149,672
152,667
159,664
174,229
170,520
163,645
162,375
163,905
165,824
153,084
155,378
155,378153,084165,824163,905162,375163,645170,520174,229159,664152,667149,672144,127125,638120,644113,721111,38186,94284,93485,31684,60183,27775,06574,03576,77166,56678,78968,90269,61100056,9654,8672,524
   > Total Current Liabilities 
2,524
4,103
10,806
0
0
0
15,350
23,472
23,474
21,329
32,952
29,638
24,629
20,053
18,555
15,362
14,882
18,373
21,104
20,050
23,035
25,039
21,964
24,184
29,636
36,560
39,679
40,383
38,653
24,057
18,308
18,058
13,895
15,152
15,15213,89518,05818,30824,05738,65340,38339,67936,56029,63624,18421,96425,03923,03520,05021,10418,37314,88215,36218,55520,05324,62929,63832,95221,32923,47423,47215,35000010,8064,1032,524
       Short-term Debt 
0
0
38,650
38,650
0
0
340
1,650
1,100
2,750
4,600
6,850
550
295
300
609
689
2,414
3,303
4,650
5,973
8,585
2,924
7,489
10,663
15,071
19,106
17,523
18,709
4,973
412
437
479
507
5074794374124,97318,70917,52319,10615,07110,6637,4892,9248,5855,9734,6503,3032,4146896093002955506,8504,6002,7501,1001,6503400038,65038,65000
       Short Long Term Debt 
0
0
38,650
38,650
0
0
45,507
1,650
1,100
2,750
4,600
6,850
550
0
0
0
0
1,750
2,575
3,863
5,150
7,725
2,025
6,563
9,750
14,225
18,700
17,195
18,362
4,606
22
23
24
25
252423224,60618,36217,19518,70014,2259,7506,5632,0257,7255,1503,8632,5751,75000005506,8504,6002,7501,1001,65045,5070038,65038,65000
       Accounts payable 
1,815
2,364
6,638
0
0
0
9,601
10,989
21,140
12,337
20,436
22,088
20,034
14,202
12,274
10,283
8,787
9,169
7,089
6,687
8,100
6,215
8,314
8,496
8,887
11,072
9,946
12,440
10,689
9,994
8,926
10,523
5,696
7,572
7,5725,69610,5238,9269,99410,68912,4409,94611,0728,8878,4968,3146,2158,1006,6877,0899,1698,78710,28312,27414,20220,03422,08820,43612,33721,14010,9899,6010006,6382,3641,815
       Other Current Liabilities 
90
867
4,168
0
0
0
4,062
9,663
2,614
5,461
7,195
2,587
3,445
4,721
5,175
3,807
4,603
6,068
10,019
8,276
8,320
9,472
9,961
6,600
8,487
9,643
9,114
5,655
5,263
6,453
7,082
5,114
6,292
5,552
5,5526,2925,1147,0826,4535,2635,6559,1149,6438,4876,6009,9619,4728,3208,27610,0196,0684,6033,8075,1754,7213,4452,5877,1955,4612,6149,6634,0620004,16886790
   > Long-term Liabilities 
0
0
0
0
0
0
54,261
45,430
55,315
45,237
43,819
44,397
50,436
63,224
66,046
69,954
70,052
68,569
90,277
93,671
97,609
100,599
122,163
125,488
123,031
123,104
134,550
130,137
124,992
138,318
145,597
147,766
139,189
140,226
140,226139,189147,766145,597138,318124,992130,137134,550123,104123,031125,488122,163100,59997,60993,67190,27768,56970,05269,95466,04663,22450,43644,39743,81945,23755,31545,43054,261000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
42,603
40,742
46,884
59,775
60,338
60,922
61,505
60,346
0
34,193
34,070
32,673
0
0
43,821
0
0
25,196
20,801
0
0
0
0
0
0000020,80125,1960043,8210032,67334,07034,193060,34661,50560,92260,33859,77546,88440,74242,6030000000000
       Other Liabilities 
0
764
7,509
0
0
0
8,754
8,091
9,985
1,183
1,216
3,655
3,552
3,449
5,708
5,608
5,307
5,176
53,102
56,843
61,124
65,741
68,666
76,098
77,708
83,089
97,563
99,235
98,581
0
0
0
0
0
0000098,58199,23597,56383,08977,70876,09868,66665,74161,12456,84353,1025,1765,3075,6085,7083,4493,5523,6551,2161,1839,9858,0918,7540007,5097640
       Deferred Long Term Liability 
0
1,092
0
0
0
0
1,050
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000001,05000001,0920
> Total Stockholder Equity
-17,493
-20,924
-95,967
-95,967
0
0
-26,495
-22,820
-38,948
23,444
10,080
-6,056
-24,657
-34,459
-6,122
-20,829
-21,388
-36,519
-48,497
-51,798
-53,769
-60,345
-82,134
-93,143
-96,357
-107,819
-118,554
-109,235
-106,651
-102,927
-106,487
-36,301
-35,479
-45,420
-45,420-35,479-36,301-106,487-102,927-106,651-109,235-118,554-107,819-96,357-93,143-82,134-60,345-53,769-51,798-48,497-36,519-21,388-20,829-6,122-34,459-24,657-6,05610,08023,444-38,948-22,820-26,49500-95,967-95,967-20,924-17,493
   Common Stock
11,088
11,243
11,243
0
0
0
12,727
20
20
25
25
25
25
25
34
34
34
34
35
36
39
40
41
41
53
54
55
56
62
67
69
90
91
91
91919069676256555453414140393635343434342525252525202012,72700011,24311,24311,088
   Retained Earnings -346,159-334,650-331,905-319,077-310,966-308,931-303,139-311,207-298,855-286,318-270,017-256,796-227,851-213,296-200,929-186,257-165,889-149,338-147,004-130,474-117,838-99,426-78,954-61,376-47,432-32,394-23,201-120,093000-108,670-32,167-28,581
   Capital Surplus 
0
0
0
0
0
0
0
0
-6,574
70,851
71,431
72,873
74,744
83,354
124,318
126,141
127,916
129,336
137,725
149,095
159,488
167,466
174,621
0
189,908
0
0
193,848
202,218
0
0
0
0
0
00000202,218193,84800189,9080174,621167,466159,488149,095137,725129,336127,916126,141124,31883,35474,74472,87371,43170,851-6,57400000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
44,732
33,306
27,136
105,294
106,622
108,800
111,382
120,687
162,362
164,899
167,374
169,507
137,725
186,927
198,003
167,466
174,621
176,833
189,908
190,982
192,598
193,848
202,218
207,972
212,521
295,514
299,080
300,648
300,648299,080295,514212,521207,972202,218193,848192,598190,982189,908176,833174,621167,466198,003186,927137,725169,507167,374164,899162,362120,687111,382108,800106,622105,29427,13633,30644,732000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue50,583
Cost of Revenue-20,831
Gross Profit29,75229,752
 
Operating Income (+$)
Gross Profit29,752
Operating Expense-44,854
Operating Income-15,102-15,102
 
Operating Expense (+$)
Research Development13,104
Selling General Administrative31,750
Selling And Marketing Expenses0
Operating Expense44,85444,854
 
Net Interest Income (+$)
Interest Income16,321
Interest Expense-7,462
Other Finance Cost-0
Net Interest Income8,859
 
Pretax Income (+$)
Operating Income-15,102
Net Interest Income8,859
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-7,625-22,579
EBIT - interestExpense = -7,625
-7,625
-408
Interest Expense7,462
Earnings Before Interest and Taxes (EBIT)-163-163
Earnings Before Interest and Taxes (EBITDA)1,182
 
After tax Income (+$)
Income Before Tax-7,625
Tax Provision-245
Net Income From Continuing Ops-7,870-7,870
Net Income-7,870
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses65,685
Total Other Income/Expenses Net7,477-8,859
 

Technical Analysis of Aquestive
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aquestive. The general trend of Aquestive is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aquestive's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aquestive Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 4.36 < 5.59 < 5.8.

The bearish price targets are: 4.1 > 3.95 > 3.02.

Tweet this
Aquestive Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aquestive Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aquestive Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aquestive Therapeutics Inc. The current macd is -0.10972801.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aquestive price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aquestive. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aquestive price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aquestive Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAquestive Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aquestive Therapeutics Inc. The current adx is 13.78.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aquestive shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Aquestive Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aquestive Therapeutics Inc. The current sar is 5.285.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aquestive Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aquestive Therapeutics Inc. The current rsi is 38.93. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Aquestive Therapeutics Inc Daily Relative Strength Index (RSI) ChartAquestive Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aquestive Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aquestive price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Aquestive Therapeutics Inc Daily Stochastic Oscillator ChartAquestive Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aquestive Therapeutics Inc. The current cci is -132.57706034.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Aquestive Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAquestive Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aquestive Therapeutics Inc. The current cmo is -30.55151712.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aquestive Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAquestive Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aquestive Therapeutics Inc. The current willr is -96.06857819.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Aquestive Therapeutics Inc Daily Williams %R ChartAquestive Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aquestive Therapeutics Inc. The current atr is 0.32695322.

Aquestive Therapeutics Inc Daily Average True Range (ATR) ChartAquestive Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aquestive Therapeutics Inc. The current obv is 27,607,650.

Aquestive Therapeutics Inc Daily On-Balance Volume (OBV) ChartAquestive Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aquestive Therapeutics Inc. The current mfi is 44.28.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Aquestive Therapeutics Inc Daily Money Flow Index (MFI) ChartAquestive Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aquestive Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-31MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Aquestive Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aquestive Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.932
Ma 20Greater thanMa 504.811
Ma 50Greater thanMa 1004.956
Ma 100Greater thanMa 2004.520
OpenGreater thanClose4.400
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10